The latest update is out from Enveric Biosciences (ENVB).
Enveric Biosciences, Inc. has announced plans to exclusively out-license new chemical entities aimed at treating joint disease for both pharmaceutical and non-pharmaceutical uses. This strategic move could potentially open up new avenues for revenue and partnerships, tapping into a market focused on joint health solutions. While the term sheets are non-binding at this stage, the announcement signifies Enveric Biosciences’ commitment to expanding its portfolio and reaching new markets.
For a thorough assessment of ENVB stock, go to TipRanks’ Stock Analysis page.
